Calvin Lai

Calvin Lai has a diverse work experience that spans multiple industries. Calvin started their career at the Center for Research in Biological Systems - Ellisman Lab, where they worked as an Academic Researcher from July 2012 to June 2014. In this role, they contributed to interdisciplinary research on cell structure and function relationships.

Calvin then joined CG Oncology, a clinical-stage biotechnology company, where they took on several roles. From September 2014 to September 2015, they worked as a Clinical Research Associate, gaining experience in clinical trials. Calvin then transitioned to a managerial position, serving as a Manager of Business Operations from September 2015 to June 2018. In this role, Calvin was responsible for coordinating various business operations within the company. Calvin then advanced to the position of Director of Business Operations from June 2018 to January 2020, where they played a key role in managing the company's business functions.

Additionally, Calvin had the opportunity to work at Perseverance Capital Management as an Associate from May 2017 onwards. Calvin was involved in asset management and pursued an evidence-based investment approach primarily in the healthcare sector.

Lastly, Calvin served as the VP of Business Development at InnoDT, Inc. from January 2018 to September 2018. In this role, they played a vital role in developing partnerships and creating strategies to prevent and identify fraudulent activity using the company's proprietary technologies.

Overall, Calvin Lai has gained extensive experience in roles related to research, clinical trials, business operations, asset management, and business development across various industries.

Calvin Lai has been a part of the UC San Diego Chancellor's Scholars Program, although the specific duration is not provided. Calvin further pursued their education at UC San Diego, where they obtained a Bachelor of Science degree in Human Biology. No start or end years were mentioned for either educational experience.